Founded in December 2009, Kayudi Biotechnology (Beijing) Co., Ltd. is a national high-tech enterprise dedicated to research, development, production and sales of genetic and molecular diagnostic systems. In 2013, Kayudi was selected as “the most promising entrepreneurial enterprise for overseas studentsâ€. In 2015, Kayudi ranked 16th among the top 50 most valuable investment companies. The molecular diagnostics industry is developing rapidly, and the industry has high technical barriers. In recent years, molecular diagnostics has been the fastest growing sub-sector in the in vitro diagnostic industry. According to the "China Bio-industry Development Report", in 2010, China's molecular diagnostics accounted for 8.9% of the global in vitro diagnostic products market, about 4.45 billion US dollars, an average annual growth rate of 17% in the past decade. At present, China has issued a number of policies for grading diagnosis and treatment and precision medical treatment to solve the problem of uneven distribution of medical resources and overcrowding of large hospitals. Molecular diagnostic technology has fast, accurate diagnostic features, but it has a high technical threshold. The advantages of Cayudi products are portable, fast and accurate, and can be used for emergency screening and chronic disease screening. The main principle of molecular diagnosis is the use of molecular biology methods to detect changes in the structure or expression level of genetic material in patients, including DNA, RNA and protein. Molecular diagnosis is the main method of predictive diagnosis. At present, Kayudi's molecular detection platform includes portable fluorescent quantitative PCR Mini8 Plus and "one-step" nucleic acid-free extraction reagents, which can be applied to the detection of many diseases and human genetics, including infectious disease screening and tumor related. Screening for pathogens and individualized medication guidelines. After the medical staff collects the blood or saliva sample for the user, the sample is placed in the PCR instrument, and the PCR instrument performs sample analysis and issues a test report at the computer terminal connected thereto. The complete test process takes approximately 20 minutes. And the "one-step" molecular detection platform is a fully enclosed system, which can avoid the artificial pollution caused by the experiment and improve the detection accuracy. "Some cancers have a lot to do with viral infections. For example, cervical cancer has been confirmed to be caused by HPV infection, and infection with Helicobacter pylori HP increases the risk of gastric cancer. Therefore, early detection of related viruses can achieve cancer. Kaydi hopes that everyone can benefit from molecular diagnosis," said Li Xiang, founder and CEO of Kayudi. Fixed Uvss ,Under Vehicle Scanner Equipment,Car Surveillance System,Plate System Scanner Shenzhen Unisec Technology Co.,ltd , https://www.uniqscansecurity.com
